Catalysts · AXSM · CIK 1579428 · page 2 of 2

AXSM catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on AXSM PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
Feb 2025Month disclosedSYMBRAVO® (meloxicam-rizatriptan)AXSMTopline readout—PositiveSEC 8-K Exhibit 99.1
January 31, 2025AXS-07AXSMPDUFA date—ScheduledSEC 8-K Exhibit 99.1
January 30, 2025Symbravo (meloxicam; rizatriptan benzoate)AXSMFDA approval—ApprovedopenFDA Drugs@FDA
January 30, 2025SYMBRAVO® (meloxicam-rizatriptan)AXSMFDA approvalcentral nervous systemApprovedSEC Form 8-K
January 13, 2025—AXSMEarnings—CompletedSEC 8-K Exhibit 99.1
Q1 2025Quarter disclosed—AXSMTopline readout—ScheduledSEC 8-K Exhibit 99.1
Q1 2025Quarter disclosedSUNOSI® (solriamfetol)AXSMTopline readoutprior inadequate response to oral CGRP inhibitorsScheduledSEC 8-K Exhibit 99.1
Q1 2025Quarter disclosedSYMBRAVO® (meloxicam-rizatriptan)AXSMTopline readoutprior inadequate response to oral CGRP inhibitorsScheduledSEC 8-K Exhibit 99.1
Q1 2025Quarter disclosedesreboxetine (AXS-14)AXSMNDA/BLA submission—ScheduledSEC 8-K Exhibit 99.1
November 12, 2024—AXSMEarnings—CompletedSEC 8-K Exhibit 99.1
Nov 2024Month disclosedesreboxetine (AXS-14)AXSMNDA/BLA submission—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedAXS-07AXSMPDUFA date—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedreboxetine (AXS-12)AXSMTopline readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedAUVELITY (dextromethorphan-bupropion)AXSMTopline readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedAXS-07AXSMTopline readout—ScheduledSEC 8-K Exhibit 99.1
Mar 2024Month disclosedreboxetine (AXS-12)AXSMTopline readout—PositiveSEC Form 10-Q
Sep 2022Month disclosedAUVELITY (dextromethorphan-bupropion)AXSMTrial startAD agitationCompletedSEC Form 10-K
August 18, 2022Auvelity (bupropion hydrochloride; dextromethorphan hydrobromide)AXSMFDA approval—ApprovedopenFDA Drugs@FDA
Aug 2022Month disclosedAUVELITY (dextromethorphan-bupropion)AXSMFDA approvalMDD in adultsApprovedSEC Form 10-K
Every catalyst is quoted from AXSM’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.